WBR0506: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 21: Line 21:
|SubCategory=Reproductive
|SubCategory=Reproductive
|Prompt=A 60-year-old patient comes to the outpatient clinic complaining of increased urination throughout the night and difficulty starting and stopping the stream of urine.  He was diagnosed with hypertension 10 years ago, and is currently taking amlodipine.  His vitals are: 67 pulse/min, 16 respirations/min, blood pressure 135/85mmHg and  temperature 37C.  His physical exam is unremarkable.  The patient’s primary care physician orders a PSA (prostate-specific antigen), which is increased.  Which of the following is true about the most likely diagnosis causing this patient’s symptoms?
|Prompt=A 60-year-old patient comes to the outpatient clinic complaining of increased urination throughout the night and difficulty starting and stopping the stream of urine.  He was diagnosed with hypertension 10 years ago, and is currently taking amlodipine.  His vitals are: 67 pulse/min, 16 respirations/min, blood pressure 135/85mmHg and  temperature 37C.  His physical exam is unremarkable.  The patient’s primary care physician orders a PSA (prostate-specific antigen), which is increased.  Which of the following is true about the most likely diagnosis causing this patient’s symptoms?
|Explanation=Common in men > 50 years of age. Hyperplasia (not hypertrophy) of the prostate gland. May be due to an age-related i in estradiol with possible sensitization of the prostate to the growthpromoting effects of DHT Characterized by a nodular enlargement of the periurethral (lateral and middle) lobes, which compress the urethra into a vertical slit. Often presents with increased frequency of urination, nocturia, difficulty starting and stopping the stream of urine, and dysuria.
|Explanation=Beningn prostatic hyperplasia (BPH) is common in men older than 50 years old. Clinically it presents with increased frequency of urination, nocturia, difficulty starting and stopping the stream of urine, and dysuria. It can lead to distention and urinary bladder hypertrophy, hydronephrosis, and subsequent urinary tract infections. It is not considered a premalignant lesion. Microscopically the gland presents hyperplasia, not hypertrophy.  Its etiology may be due to an age-related increase in estradiol and DHT.  It is characterized by a nodular enlargement of the peri-urethral, which include the lateral and middle lobes which compress the urethra.  It causes an increase in the free prostate-specific antigen (PSA). Treatment: arantagonists (terazosin, tamsulosin), which cause relaxation of smooth muscle; finasteride.
May lead to distention and hypertrophy of the bladder, hydronephrosis, and UTis. Not considered a premalignant lesion. i free prostate-specific antigen (PSA). Treatment: arantagonists (terazosin, tamsulosin), which cause relaxation of smooth muscle; finasteride.


ADC: Common in men > 50 years of age. Arises most often from the posterior lobe (peripheral zone)
Prostatic cancer it is commonly caused by adenocarcinoma (ADC), which incidence increases with age. Anatomically it is commonly located in the posterior lobe or peripheral zone, therefore accesible to the digital rectal examination of the prostate gland, which is felt as a hard nodule. Prostatic acid phosphatase (PAP) and PSA are used as tumor markers (increase in total PSA, with decrease in free fraction of PSA). Lately it can cause osteoblastic metastases which can be presented aslower back pain and an increase in serum alkaline phosphatase and PSA.
of the prostate gland and is most frequently diagnosed by digital rectal examination
<font color="MediumBlue"><font size="4">'''Educational Objective:'''</font></font>
(hard nodule) and prostate biopsy. Prostatic acid phosphatase (PAP) and PSA are useful tumor markers (i total PSA, with J, fraction of free PSA). Osteoblastic metastases in bone may develop in late stages, as indicated by
# BPH is frequently located in the periurethral lobes causing urinary obstructive symptoms. It increases free PSA
lower back pain and an i in serum alkaline phosphatase and PSA.
# Prostatic cancer is frequently located in the posterior lobe accesible by DRE. It increases total PSA, but decreases free PSA
<br>'''References:''' First Aid 2013 reproductive chapter
[[File:Gray1153.png|center]]
[[File:Gray1153.png|center]]
|AnswerA=Prostatic cancer is preceded by benign prostatic hypertrophy
|AnswerA=Prostatic cancer is preceded by benign prostatic hypertrophy

Revision as of 20:22, 24 September 2013

 
Author [[PageAuthor::Gonzalo A. Romero, M.D. [1]]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pathology
Sub Category SubCategory::Reproductive
Prompt [[Prompt::A 60-year-old patient comes to the outpatient clinic complaining of increased urination throughout the night and difficulty starting and stopping the stream of urine. He was diagnosed with hypertension 10 years ago, and is currently taking amlodipine. His vitals are: 67 pulse/min, 16 respirations/min, blood pressure 135/85mmHg and temperature 37C. His physical exam is unremarkable. The patient’s primary care physician orders a PSA (prostate-specific antigen), which is increased. Which of the following is true about the most likely diagnosis causing this patient’s symptoms?]]
Answer A AnswerA::Prostatic cancer is preceded by benign prostatic hypertrophy
Answer A Explanation [[AnswerAExp::Incorrect. See overall explanation]]
Answer B AnswerB::Prostatic cancer increases both total PSA and free PSA
Answer B Explanation [[AnswerBExp::Incorrect.See overall explanation]]
Answer C AnswerC::Benign prostatic hyperplasia is localized frequently in the posterior lobe of the prostate
Answer C Explanation [[AnswerCExp::Incorrect.See overall explanation]]
Answer D AnswerD::Prostatic cancer is localized frequently in the lateral lobes of the prostate
Answer D Explanation [[AnswerDExp::Incorrect.See overall explanation]]
Answer E AnswerE::Benign prostatic hyperplasia increases free PSA
Answer E Explanation [[AnswerEExp::Correct.See overall explanation]]
Right Answer RightAnswer::E
Explanation [[Explanation::Beningn prostatic hyperplasia (BPH) is common in men older than 50 years old. Clinically it presents with increased frequency of urination, nocturia, difficulty starting and stopping the stream of urine, and dysuria. It can lead to distention and urinary bladder hypertrophy, hydronephrosis, and subsequent urinary tract infections. It is not considered a premalignant lesion. Microscopically the gland presents hyperplasia, not hypertrophy. Its etiology may be due to an age-related increase in estradiol and DHT. It is characterized by a nodular enlargement of the peri-urethral, which include the lateral and middle lobes which compress the urethra. It causes an increase in the free prostate-specific antigen (PSA). Treatment: arantagonists (terazosin, tamsulosin), which cause relaxation of smooth muscle; finasteride.

Prostatic cancer it is commonly caused by adenocarcinoma (ADC), which incidence increases with age. Anatomically it is commonly located in the posterior lobe or peripheral zone, therefore accesible to the digital rectal examination of the prostate gland, which is felt as a hard nodule. Prostatic acid phosphatase (PAP) and PSA are used as tumor markers (increase in total PSA, with decrease in free fraction of PSA). Lately it can cause osteoblastic metastases which can be presented as: lower back pain and an increase in serum alkaline phosphatase and PSA. Educational Objective:

  1. BPH is frequently located in the periurethral lobes causing urinary obstructive symptoms. It increases free PSA
  2. Prostatic cancer is frequently located in the posterior lobe accesible by DRE. It increases total PSA, but decreases free PSA


References: First Aid 2013 reproductive chapter


Educational Objective:
References: ]]

Approved Approved::No
Keyword WBRKeyword::Prostate cancer, WBRKeyword::BPH
Linked Question Linked::
Order in Linked Questions LinkedOrder::